Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

7 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Predictors of Response to Vedolizumab in Patients with Ulcerative Colitis: Results from the Greek VEDO-IBD Cohort.
Bamias G, Kokkotis G, Gizis M, Kapizioni C, Karmiris K, Koureta E, Kyriakos N, Leonidakis G, Makris K, Markopoulos P, Michalopoulos G, Michopoulos S, Papaconstantinou I, Polymeros D, Siakavellas SI, Triantafyllou K, Tsironi E, Tsoukali E, Tzouvala M, Viazis N, Xourafas V, Zacharopoulou E, Zampeli E, Zografos K, Papatheodoridis G, Mantzaris G. Bamias G, et al. Among authors: xourafas v. Dig Dis Sci. 2022 Mar;67(3):1007-1017. doi: 10.1007/s10620-021-06907-5. Epub 2021 Mar 9. Dig Dis Sci. 2022. PMID: 33751325 Free PMC article.
The IBD-F Patient Self-Assessment Scale Accurately Depicts the Level of Fatigue and Predicts a Negative Effect on the Quality of Life of Patients With IBD in Clinical Remission.
Varbobitis I, Kokkotis G, Gizis M, Perlepe N, Laoudi E, Bletsa M, Bekiari D, Koutsounas I, Kounadis G, Xourafas V, Lagou S, Kolios G, Papakonstantinou I, Bamias G. Varbobitis I, et al. Among authors: xourafas v. Inflamm Bowel Dis. 2021 May 17;27(6):826-835. doi: 10.1093/ibd/izaa201. Inflamm Bowel Dis. 2021. PMID: 32766770
Response to Anti-α4β7 Blockade in Patients With Ulcerative Colitis Is Associated With Distinct Mucosal Gene Expression Profiles at Baseline.
Gazouli M, Dovrolis N, Bourdakou MM, Gizis M, Kokkotis G, Kolios G, Michalopoulos G, Michopoulos S, Papaconstantinou I, Tzouvala M, Viazis N, Xourafas V, Zacharopoulou E, Zampeli E, Mantzaris G, Papatheodoridis G, Bamias G. Gazouli M, et al. Among authors: xourafas v. Inflamm Bowel Dis. 2022 Jan 5;28(1):87-95. doi: 10.1093/ibd/izab117. Inflamm Bowel Dis. 2022. PMID: 34042157
Correction: DARING-B: discontinuation of effective entecavir or tenofovir disoproxil fumarate long-term therapy before HBsAg loss in non-cirrhotic HBeAg-negative chronic hepatitis B.
Papatheodoridis GV, Rigopoulou EI, Papatheodoridi M, Zachou K, Xourafas V, Gatselis N, Hadziyannis E, Vlachogiannakos J, Manolakopoulos S, Dalekos GN. Papatheodoridis GV, et al. Among authors: xourafas v. Antivir Ther. 2018;23(8):711. doi: 10.3851/IMP3261. Antivir Ther. 2018. PMID: 30091421 No abstract available.
DARING-B: discontinuation of effective entecavir or tenofovir disoproxil fumarate long-term therapy before HBsAg loss in non-cirrhotic HBeAg-negative chronic hepatitis B.
Papatheodoridis GV, Rigopoulou EI, Papatheodoridi M, Zachou K, Xourafas V, Gatselis N, Hadziyannis E, Vlachogiannakos J, Manolakopoulos S, Dalekos GN. Papatheodoridis GV, et al. Among authors: xourafas v. Antivir Ther. 2018;23(8):677-685. doi: 10.3851/IMP3256. Antivir Ther. 2018. PMID: 30044765
Autoantibodies in type 1 diabetes.
Heras P, Mantzioros M, Mendrinos D, Heras V, Hatzopoulos A, Xourafas V, Kritikos K, Karagiannis S. Heras P, et al. Among authors: xourafas v. Diabetes Res Clin Pract. 2010 Nov;90(2):e40-2. doi: 10.1016/j.diabres.2010.08.015. Epub 2010 Sep 15. Diabetes Res Clin Pract. 2010. PMID: 20833441